Stock ADXS AYALA PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Ayala Pharmaceuticals, Inc.

Equities

ADXS

US0076244062

Market Closed - OTC Markets
Other stock markets
 20:29:40 10/05/2024 BST 		5-day change 1st Jan Change
0.437 USD -21.96% Intraday chart for Ayala Pharmaceuticals, Inc. -21.26% -34.48%
04-16 Ayala Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
04-16 Ayala Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Ayala Pharmaceuticals Files Form 15 to Voluntarily Deregister and Suspend its Reporting Obligations
AQ
Ayala Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Ayala Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
North American Morning Briefing : Stock Futures Edge Lower Ahead of PPI Inflation Gauge
DJ
North American Morning Briefing : Focus Turns to -2-
DJ
Ayala Pharmaceuticals, Inc. Announces Departure of Roy Golan as Chief Financial Officer, Effective from June 25, 2024
CI
Andres Guttierez, Chief Medical Officer and Executive Vice President, Departs from Ayala Pharmaceuticals, Inc
CI
North American Morning Briefing : Stocks Set for -2-
DJ
Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome
AQ
Immunome, Inc. completed the acquisition of Assets from Ayala Pharmaceuticals, Inc..
CI
North American Morning Briefing : Fed's Preferred -2-
DJ
North American Morning Briefing : Nvidia Ignites -2-
DJ
Ayala Pharmaceuticals Announces Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors
AQ
Ayala Pharmaceuticals, Inc. Announces Completion of Enrollment in Phase 3 Ringside Study Evaluating AL102 in Desmoid Tumors
CI
Sector Update: Health Care Stocks Gain Late Afternoon
MT
Top Midday Gainers
MT
Immunome to Acquire Potential Desmoid Tumor Treatment From Ayala Pharmaceuticals; Shares Climb
MT
Immunome To Acquire AL102, A Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals
AQ
Immunome, Inc. entered into a definitive asset purchase agreement to acquire Assets from Ayala Pharmaceuticals, Inc. for $94.2 million.
CI
North American Morning Briefing : Stock Futures -2-
DJ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ADXS Stock
  4. News Ayala Pharmaceuticals, Inc.